Dr. Cadavid is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
61 N Beacon St
Boston, MA 02134Phone+1 617-599-0755
Education & Training
MedStar Health/Georgetown University HospitalResidency, Neurology, 1995 - 1998
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineInternship, Internal Medicine, 1994 - 1995
Pontifical Xavierian UniversityClass of 1991
Certifications & Licensure
MA State Medical License 2013 - 2026
NJ State Medical License 1999 - 2009
DC State Medical License 1998 - 2000- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Start of enrollment: 2003 Jan 01
Publications & Presentations
PubMed
- 114 citationsCerebral beta amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsiesDiego Cadavid, Hernando Mena, Kelly K. Koeller, Robert A. Frommelt
Journal of Neuropathology and Experimental Neurology. 2000-09-01 - 70 citationsThe chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathyMike P. Wattjes, Nancy Richert, Joep Killestein, Marlieke de Vos, Esther Sanchez
Multiple Sclerosis. 2013-11-05 - 132 citationsClinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.Patrick Vermersch, Ludwig Kappos, R. Gold, John Foley, Tomas Olsson
Neurology. 2011-05-17
Press Mentions
Verge Genomics to Incorporate Emerald Digital Health Technology into Its ALS Phase 1b Proof-of-Concept Clinical TrialMay 24th, 2023- X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021June 11th, 2021
- Immune Regulation Makes Peter Greenleaf Chairman and Assembles a Quintet of New Execs; Bob Coughlin Moves on from MassBio to JLLDecember 18th, 2020
- Join now to see all
Grant Support
- Protective Role Of Interleukin 10 In NeuroborreliosisNational Institute Of Neurological Disorders And Stroke2008–2009
- Borrelia Lipoproteins With The Cerebral MicrocirculationNational Institute Of Neurological Disorders And Stroke2006–2007
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
